GOTHENBURG, Sweden--(BUSINESS WIRE)-- Regulatory News:
Cellectis stem cells, a Business Unit of Cellectis Group (Alternext:ALCLS.PA - News), a premier provider of stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEPTM.
The hiPS-HEPTM demonstrate high reproducibility, homogeneity and a long life span of stable CYP activity, making them the ideal platform for various in vitro applications including drug discovery, toxicity testing and vaccine development. The hiPS-HEP™ are human hepatocyte-like cells derived from human induced Pluripotent Stem (iPS) cells under strict quality controlled and ethically approved procedures.
“Due to their high relevance in various industrial applications it makes the hiPS-HEP™ a really promising system for research and development,” said Johan Hyllner, CSO of Cellectis stem cells. “The pharmaceutical industry has a great need for better and more clinically relevant models early in the drug development process to predict hepatotoxicity, find new drug targets and develop new vaccines.”
“This novel product is the fruition of Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It illustrates our ambitions and the momentum of our future development in this field,” said André Choulika, Chairman and CEO of Cellectis.
About Cellectis stem cells:
Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis AB and Ectycell SAS, possesses broad expertise in pluripotent stem cells, including iPS cell technology, genetic engineering and specialised cells. Cellectis stem cells is developing stem cell derived products and related services for drug discovery, toxicity testing and regenerative medicine applications.
For more information visit www.cellartis.com and www.cellectis.com
About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code:ALCLS.PA - News).
To find out more, visit www.cellectis.com.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Contact:
Cellectis
Mathieu Simon, +33 (0)1 81 69 16 00
Senior Vice President
media@cellectis.com
or
Cellectis
Philippe Valachs, +33 (0)1 81 69 16 00
Company Secretary
media@cellectis.com
or
Profile PR
Leslie Boutin / Hina de Soultrait, +33 (0)1 56 26 72 00
lboutin@profilepr.fr
hdesoultrait@profilepr.fr
